Hot Investor Mandate: China-Based Healthcare Company Seeks Innovative Therapeutics Addressing Indications of High Unmet Medical Need

3 Oct

A healthcare company in China looks for therapeutic assets in late clinical stages (after completion of Phase 2) for in-licensing rights for China market, and in preclinical stage for company formation, especially with cutting technology platforms.  Preclinical in vivo data for early stage assets are critical.

In the life sciences, the firm is currently looking for innovative therapeutics companies. The firm will focus on assets in five indication areas: oncology, CNS, cardiovascular, metabolic disease, and infectious diseases. For the type of modality, the firm is open to companies developing small molecule, gene therapy, biologics, and cell therapy.

The firm is interested in privately held life science companies with experienced management teams and innovative technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: